Clinical Trial Update: Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009) [Phase 2]

View source ↗

Summary

Phase 2 study LEAP-009 evaluated lenvatinib plus pembrolizumab versus standard chemotherapy and lenvatinib alone in recurrent/metastatic head and neck squamous …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• LENVIMA (lenvatinib)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Squamous Cell Carcinoma of Head and Neck | Phase 2 | Status: COMPLETED | Results posted: 2025-05-25